Paclitaxel
- Generic Name
- Paclitaxel
- Brand Names
- Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
- Drug Type
- Small Molecule
- Chemical Formula
- C47H51NO14
- CAS Number
- 33069-62-4
- Unique Ingredient Identifier
- P88XT4IS4D
- Background
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
- Indication
Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
- Associated Therapies
- -
Neoadjuvant Concomitant Modulated Electro-hyperthermia in HER2-negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-06-05
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Semmelweis University
- Target Recruit Count
- 71
- Registration Number
- NCT05889390
- Locations
- 🇭🇺
Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary
A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Biotheus Inc.
- Target Recruit Count
- 99
- Registration Number
- NCT05879068
- Locations
- 🇨🇳
Peking University Cancer Hospital, Beijing, China
🇨🇳Hunan Cancer Hospital, Changsha, China
🇨🇳Sichuan Provincial People's Hospital, Chengdu, China
Effect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2023-05-25
- Target Recruit Count
- 82
- Registration Number
- NCT05872412
- Locations
- 🇧🇩
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Sutro Biopharma, Inc.
- Target Recruit Count
- 600
- Registration Number
- NCT05870748
- Locations
- 🇺🇸
Texas Oncology, Dallas, Texas, United States
🇺🇸Ohio State University Center, Columbus, Ohio, United States
🇺🇸Baptist Health South Florida (BHSF) - Miami Cancer Institute, Miami, Florida, United States
Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-05-10
- Last Posted Date
- 2023-05-10
- Target Recruit Count
- 30
- Registration Number
- NCT05853172
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 876
- Registration Number
- NCT05841381
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
- Conditions
- Interventions
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 654
- Registration Number
- NCT05840211
- Locations
- 🇰🇷
Samsung Medical Center, Gangnam-Gu, Korea, Republic of
🇲🇽Centro de Atención e Investigación Clínica en Oncología, Yucatán, Mexico
🇵🇱Wojewodzki Szpital Specjalistyczny lm. Stefana Kardynala Wyszynsklego SPZOZ w Lublinie, Lublin, Poland
A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.
- Conditions
- Interventions
- First Posted Date
- 2023-04-28
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20605
- Registration Number
- NCT05834348
- Locations
- 🇳🇴
Pfizer Norway, Oslo, Norway
First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)
- Conditions
- Interventions
- First Posted Date
- 2023-04-27
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- National Cancer Center, Japan
- Target Recruit Count
- 35
- Registration Number
- NCT05832827
- Locations
- 🇯🇵
National Cancer Center Hospital, Chuo, Tokyo, Japan
First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- Onward Therapeutics
- Target Recruit Count
- 150
- Registration Number
- NCT05828459
- Locations
- 🇫🇷
Saint-Eloi Hospital - Montpellier (CHU), Montpellier, France
🇫🇷Saint-Joseph Hospital - Paris, Paris, France
🇫🇷ICM - Montpellier, Montpellier, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.